Table 5.
Demographics of Patients Using and Not Using Disease-Modifying Therapy
| Demographics | On DMT | Not on DMT | p-value |
|---|---|---|---|
| Females: Males (% Female)a | 283:110 (72.0%) | 77:38 (67.0%)a | 0.30b |
| Disease coursea | |||
| Relapsing-remitting | 270 (68.7%) | 65 (56.5%) | <0.001c |
| Secondary progressive | 106 (27.0%) | 32 (27.8%) | |
| Primary Progressive | 17 (4.3%) | 18 (15.7%) | |
| Race/Ethnicity (%) | 0.26c | ||
| Caucasian | 361 (92.1%) | 109 (95.6%) | |
| African American | 21 (5.4%) | 1 (0.9%) | |
| Hispanic Latino | 7 (1.8%) | 2 (1.8%) | |
| Asian | 1 (0.3%) | 1 (0.9%) | |
| Other | 2 (0.5%) | 1 (0.9%) | |
| Age, years | 47.3 ± 11.3 | 48.9 ± 10.6 | 0.18d |
| Disease Duration, years | 15.0 ± 10.6 | 15.8 ± 10.3 | 0.46d |
| Treatment Duration, years | 4.38 ± 3.89 | 2.30 ± 0.366 | 0.079d |
| Median EDSS (IQR) | 3.0 (4.5) | 3.5 (3.8) | 0.053e |
a
DMT usage data not available for n = 14 subjects for gender and disease course crosstabs. Race data were missing for n = 16 of 522 subjects. Treatment duration was available only for n = 11 subjects in the Not on DMT group.
b
Fisher's exact test.
c
Chi-squared test.
d
Independent sample t-test.
e
Mann–Whitney test.
DMT, disease-modifying therapies.